Figure 1.

Liraglutide improved hepatic lipid accumulation, metabolic disorder, and liver function in HFD-induced mice model of NAFLD. (a) Liver histology was observed using hematoxylin and eosin staining. The representative images were shown (magnification ×200, scale 20 μm). (b) Hepatic lipid accumulation was observed using Oil Red O staining. The representative images were shown (magnification ×200, scale 20 μm). Black arrows indicated lipid droplets. (c, d, e) Metabolic parameters determined by TG, FBG, and insulin concentrations (mmol/L) in serum. (f, g, h) Liver function determined by ALT, AST, and GGT concentrations (U/L) in serum. All serous results presented as means ± SD from six independent experiments. ⁎ denotes P < 0.05, versus the NCD group; # denotes P < 0.05 versus the HFD+Veh group.